ReviewInternational journal of oncology2026
Biomarkers for oesophageal squamous cell carcinoma and the role of HPV: Multi‑omics approaches and current evidence (Review).
Review in International journal of oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- An Update Comprehensive Review on Epigenetic Modifications and Therapies in Autoimmune Diseases.Clinical reviews in allergy & immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oesophageal squamous cell carcinoma (ESCC) represents a major global health burden, particularly in regions with high incidence rates, significantly affecting patient quality of life and survival outcomes. Recent advances in multi‑omics technologies have highlighted their potential in identifying prognostic markers for ESCC. Concurrently, the possible association between human papillomavirus (HPV) infection and ESCC development has been investigated, although epidemiological evidence remains heterogeneous and a definitive causal role has not been universally established. This narrative review examines the progress in multi‑omics approaches for identifying prognostic markers of ESCC and provides a comprehensive analysis of the latest developments in HPV detection methods. Research from genomic, transcriptomic, proteomic, epigenomic, metabolomic, and immunomic studies was synthesized highlighting both promising biomarkers and the significant heterogeneity in reported results, particularly regarding HPV prevalence rates across various geographical regions and detection methods. The research included not only offers novel insights into the pathogenesis of ESCC but also lays a theoretical foundation for early diagnosis and personalized treatment; however, most findings remain investigational and require prospective validation before clinical implementation. The clinical implications and future research directions are discussed with consideration of current limitations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.